![Prostate Cancer Foundation](data:image/svg+xml;utf8,<svg xmlns="http://www.w3.org/2000/svg" width="100%" height="100%"><rect width="100%" height="100%"><animate attributeName="fill" values="rgba(153,153,153,0.5);rgba(153,153,153,0.1);rgba(153,153,153,0.5)" dur="2s" repeatCount="indefinite" /></rect></svg>)
![Prostate Cancer Foundation](data:image/svg+xml;utf8,<svg xmlns="http://www.w3.org/2000/svg" width="250" height="148"><rect width="100%" height="100%"><animate attributeName="fill" values="rgba(153,153,153,0.5);rgba(153,153,153,0.1);rgba(153,153,153,0.5)" dur="2s" repeatCount="indefinite" /></rect></svg>)
Explore News By Topic
01/12/2021
PCF-Funded Research Inhibits Prostate Cancer Growth
New research, just published in Cancer Discovery, describes a new therapy with promising preclinical activity that is now being tested in clinical trials for very advanced prostate cancer patients. Early studies suggest this treatment has promising activity for the significant proportion of patients with advanced prostate cancer whose tumors remain... Read More
12/21/2020
Breaking News: FDA Approves First Oral Hormone Therapy for Advanced Prostate Cancer
On Friday, December 18, 2020, the US FDA approved the first oral gonadotropin-releasing hormone (GnRH) receptor antagonist, relugolix, for adult patients with advanced prostate cancer. This is an important advance because it offers another option to patients who are taking hormone therapy. One of the mainstays of treatment for high-risk... Read More
06/09/2020
New Recommendations Offer Guidance for Clinicians & Patients on Implementing Genetic Testing for Prostate Cancer
PHILADELPHIA — An international panel of experts led by researchers and thought-leaders at the Sidney Kimmel Cancer Center – Jefferson Health (SKCC) and the Department of Urology at Jefferson have published the first multidisciplinary, consensus-driven prostate cancer genetic implementation framework for the precision medicine era. The consensus framework is a... Read More
04/28/2020
Major Trial Shows Breast Cancer Drug Can Hit Prostate Cancer Achilles Heel
Olaparib, licensed for breast and ovarian cancer, is effective for some men with prostate cancer too Drug better than targeted hormone therapy in cancers with weaknesses in repairing their DNA Major clinical trial heralds approval as first gene-targeted drug in prostate cancer A drug already licensed for the treatment of... Read More
03/28/2019
Researchers Discover How a Gene Deletion Contributes to Prostate Cancer Growth
Original Press Release Issued by: Weill Cornell Medicine The deletion of a gene that normally promotes healthy cell division in the prostate encourages the growth of cancer in the gland, according to a new study by Weill Cornell Medicine investigators. The findings, published March 28 in Cancer Cell, suggest that... Read More
06/14/2018
New Study Identifies Another Opportunity for Precision Immunotherapy in Prostate Cancer
A new Prostate Cancer Foundation (PCF)-funded study published today in the scientific journal Cell has identified a new subtype of advanced prostate cancer – one which may be treatable with checkpoint immunotherapy, a type of treatment that can produce long-term remissions and even cures in many cancer types, but has... Read More
06/07/2018
New and More Sensitive Prostate Cancer Imaging on the Near Horizon
At the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, promising results were reported from a phase 2/3 clinical trial testing the accuracy of a new prostate cancer imaging method -- PSMA-PET -- for detecting sites of prostate cancer recurrence. The current standard imaging methods for detecting recurrent or... Read More
05/03/2018
PCF-funded investigators report progress on a promising new treatment for a highly lethal form of prostate cancer
Prostate cancer cells depend on androgens to grow and thrive. Because of this dependency, hormone therapy – the blockade of androgens and the androgen receptor (AR) – has been the cornerstone of prostate cancer treatment for decades. As science has progressed, therapies that are better and better at blocking these... Read More
04/02/2018
Scientists uncover “long tail” of nearly 100 genes mutated in prostate cancer
APRIL 2, 2018 -- Issued by Dana-Farber Cancer Institute. By sequencing DNA in more than 1,000 patient samples, researchers have identified a total of 97 genes significantly mutated in prostate cancer, including 70 not previously implicated in the disease. The large-scale study identified a new class of prostate cancers defined... Read More
03/14/2018
New Study indicates 18 months of androgen deprivation therapy may be optimal for locally advanced prostate cancer
Results from the RADAR clinical trial presented at the 2018 ASCO Genitourinary Cancer Symposium indicate that 18 months of ADT could very likely become the new standard of care. The RADAR trial demonstrated that 18 months of androgen deprivation therapy (ADT) is significantly better than 6 months of ADT at... Read More